Posted by Michael Wonder on 29 Nov 2023
Tisagenlecleucel for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies
29 November 2023 - NICE is unable to make a recommendation on the use of tisagenlecleucel (Kymriah) for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma after 2 or more systemic therapies.
This is because Novartis did not provide a complete evidence submission.
